Cargando…

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease

AIM: To determine the prevalence of work disability in inflammatory bowel disease (IBD), and to assess risk factors associated with work disability. METHODS: For this retrospective cohort study, we retrieved clinical data from the Dutch IBD Biobank on July 2014, containing electronic patient records...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spekhorst, Lieke M, Oldenburg, Bas, van Bodegraven, Ad A, de Jong, Dirk J, Imhann, Floris, van der Meulen-de Jong, Andrea E, Pierik, Marieke J, van der Woude, Janneke C, Dijkstra, Gerard, D’Haens, Geert, Löwenberg, Mark, Weersma, Rinse K, Festen, Eleonora A M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Retrospective Cohort Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739924/ https://www.ncbi.nlm.nih.gov/pubmed/29290654 http://dx.doi.org/10.3748/wjg.v23.i46.8182

Ejemplares similares

Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2
por: Visschedijk, Marijn C., et al.
Publicado: (2016)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes
por: Voskuil, M D, et al.
Publicado: (2020)

Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease
por: Karmi, Naomi, et al.
Publicado: (2021)

Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
por: Imhann, Floris, et al.
Publicado: (2019)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
por: Biemans, Vince B.C., et al.
Publicado: (2019)

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
por: Biemans, Vince B C, et al.
Publicado: (2020)

Long-Term Dietary Patterns Are Reflected in the Plasma Inflammatory Proteome of Patients with Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn’s Disease Exacerbations
por: Klaassen, Marjolein A Y, et al.
Publicado: (2019)

Correction to: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
por: Imhann, Floris, et al.
Publicado: (2019)

Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis
por: Simsek, Melek, et al.
Publicado: (2019)

Next-Generation Therapeutics for IBD
por: Löwenberg, Mark, et al.
Publicado: (2015)

SLC39A8 missense variant is associated with Crohn's disease but does not have a major impact on gut microbiome composition in healthy subjects
por: Collij, Valerie, et al.
Publicado: (2019)

Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
por: Loveikyte, Roberta, et al.
Publicado: (2023)

Large-scale genetic analyses in an understudied disease: haemorrhoidal disease
por: Festen, Eleonora A M, et al.
Publicado: (2021)

Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease
por: Otten, Antonius T., et al.
Publicado: (2022)

Prototype evaluation of a self-management Internet diary for patients with ulcerative colitis
por: Snoei, Lucia, et al.
Publicado: (2009)

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
por: van der Valk, Mirthe E., et al.
Publicado: (2016)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
por: Strik, Anne S., et al.
Publicado: (2019)

Genetic Association Analysis of the Functional c.714T>G Polymorphism and Mucosal Expression of Dectin-1 in Inflammatory Bowel Disease
por: de Vries, Hilbert S., et al.
Publicado: (2009)

Patient attitudes towards faecal sampling for gut microbiome studies and clinical care reveal positive engagement and room for improvement
por: Bolte, Laura A., et al.
Publicado: (2021)

Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options
por: Bourgonje, Arno R., et al.
Publicado: (2021)

Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ)
por: van der Sloot, Kimberley Wilhelmina Johanna, et al.
Publicado: (2018)

The PROactive cohort study: rationale, design, and study procedures
por: Nap- van der Vlist, Merel M., et al.
Publicado: (2022)

Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
por: Marquès Camí, Miquel, et al.
Publicado: (2021)

Mercaptopurine for the Treatment of Ulcerative Colitis: A Randomized Placebo-Controlled Trial
por: Löwenberg, Mark, et al.
Publicado: (2023)

IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
por: Momozawa, Yukihide, et al.
Publicado: (2018)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index
por: Bots, Steven, et al.
Publicado: (2021)

MOLGENIS research: advanced bioinformatics data software for non-bioinformaticians
por: van der Velde, K Joeri, et al.
Publicado: (2019)

Cohort Profile Update: Lifelines, a three-generation cohort study and biobank
por: Sijtsma, Anna, et al.
Publicado: (2021)

Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics
por: Voskuil, Michiel Dirk, et al.
Publicado: (2019)

The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease
por: Bourgonje, Arno R, et al.
Publicado: (2021)

Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease
por: Lutgens, M W M D, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_oht8vk7t2t4l0mur7ghov3dk2u